US Patent

US11173134 — Methods for the treatment of depression

Method of Use · Assigned to Janssen Pharmaceutica NV · Expires 2035-09-10 · 9y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods and dosing regimens for treating depression, particularly treatment-resistant depression and suicidality.

USPTO Abstract

The present invention is directed to methods and dosing regimens for the treatment of depression (preferably, treatment resistant depression), for the treatment of depression in a suicidal patient, and/or for the treatment and/or prevention of suicidality (e.g. suicidal ideations).

Drugs covered by this patent

esketamine-hydrochloride (ESKETAMINE HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4115`	—	esketamine-hydrochloride

Patent Metadata

Patent number: US11173134
Jurisdiction: US
Classification: Method of Use
Expires: 2035-09-10
Drug substance claim: No
Drug product claim: No
Assignee: Janssen Pharmaceutica NV
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.